News | July 05, 2023
Syngene to acquire multi-modal facility from Stelis Biopharma
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
The application is in line with Innocan's strategy to expand the scope of its combined magnesium and cannabis topical solution
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
The certification issued by the EDQM verifies the compliance of pharmaceutical substances
Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
He mentioned that Thyroid disorders are a common health problem in Jammu and Kashmir
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
